Novo Nordisk and OpenAI partner to drive AI in pharma

Novo Nordisk partners with OpenAI to integrate AI into drug development and operations, aiming to boost innovation and efficiency. Shares rose 2.8% after the announcement.

Novo Nordisk has announced a strategic partnership with OpenAI to integrate artificial intelligence across its operations, including drug discovery, development, manufacturing, and commercial activities. The collaboration aims to leverage OpenAI’s technology to analyze large volumes of complex data, identify promising pharmaceutical candidates, and reduce development times from the lab to the patient. This initiative is expected to enhance scientists’ capabilities and improve overall efficiency, though it may slow future hiring. Initial pilot programs will be launched in research, production, and business units, with full integration targeted by the end of 2026. Following the announcement, Novo Nordisk shares rose by 2.8%. While financial details were not disclosed, this move reflects a broader trend in the pharmaceutical industry to adopt AI for accelerating innovation and efficiency, despite ongoing concerns about AI’s ability to deliver measurable breakthroughs in new molecules.